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To evaluate the clinical outcomes of daptomycin therapy and adherence to treatment recommendations, 
a retrospective cohort study was conducted with patients that received daptomycin during the period 
of the study. The adherence and nonadherence to clinical guidelines were assessed through organism 
identification, dose and time of treatment, management of bacteremia, and vancomycin treatment 
failure. A multiple logistic regression model analyzed the association between independent variables 
and clinical success (dependent variable), considering 5% of statistical significance. The study 
presented 52 patients who received daptomycin for the treatment of bacteremia (21.1%) or infections 
(osteomyelitis [63.5%], synovial fluid [15.4%]). Most patients (86.5%) received daptomycin as the 
second line of treatment, and 51.9% achieved clinical success. The patients had a better chance of 
clinical success when they followed the guideline indications (OR = 16.86; 95% CI = 1.45-195.88) 
and the medication was prescribed by a specialist in infectious diseases (OR = 4.84; 95% CI = 1.11-
21.09). The study demonstrated lower clinical success than that described in the literature because of 
patients who were not eligible according to the clinical guidelines. Adherence to recommendations 
and appropriate prescription of reserve antibiotics is important in limiting early resistance, and 
avoiding clinical failure and unnecessary expenditure.
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INTRODUCTION
Bone and joint infections (e.g., osteomyelitis, 
septic arthritis, and prosthetic joint infections) are 
produced mostly by Gram-positive agents, especially 
Staphylococcus aureus and Enterococcus. These are 
complicated infections that are difficult to control 
and generally require surgical interventions and 
long antibiotic treatments (Davis, 2005; Rice, Vigo, 
2009). Several years ago, daptomycin was marketed 
as a promising bactericidal agent for many infectious 
conditions, including those seen in orthopedic hospitals.
Daptomycin is a lipopeptide antibiotic for the 
treatment of serious Gram-positive infections involving 
S. aureus, Enterococcus faecalis, and Enterococcus 
faecium, including vancomycin-resistant strains and 
methicillin-resistant S. aureus (MRSA) (Vilhena, 
Bettencourt, 2012). In 2003, the US Food and Drug 
Administration (FDA) approved it for the treatment of 
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skin and soft-tissue infections produced by Gram-positive 
coccus and for the treatment of S. aureus bacteremia 
due to infectious endocarditis (Sakoulas, 2009). The 
European Medicines Agency (EMA) recommends this 
antibiotic for Gram-positive bacterial infections, soft 
tissue infections, endocarditis, and bacterial bacteremia 
(European Medicines Agency, 2017).
A recent meta-analysis based on thirteen 
randomized controlled trials comparing daptomycin 
with other antimicrobials (e.g., vancomycin, teicoplanin, 
gentamycin) found that the efficacy of daptomycin was 
similar to the comparators with the intention to treat 
applied (He et al., 2014).
The Cubicin Outcomes Registry and Experience 
(CORE) and the European section (EUCORE) are 
two big ongoing, retrospective, post-marketing, 
noncomparative databases of daptomycin use in patients 
that had received at least one daptomycin dose. One of its 
main results was the finding of 80% daptomycin clinical 
success in patients with osteomyelitis (Gonzalez-Ruiz et 
al., 2011; Liang et al., 2014).
Orthopedic patients can benefit from daptomycin, as 
high rates of success have been reported in osteomyelitis 
and osteoarticular infections due to MRSA (Liang et al., 
2014). A case-control study carried out in patients with 
osteomyelitis (involving MRSA or not) showed that less 
recurrent infections during the six months following the 
end of antibiotics were recorded among those patients 
receiving daptomycin as compared with those receiving 
other antibiotics (Moenster et al., 2012).
In general, daptomycin is recommended as a 
therapeutic option in cases of MRSA osteomyelitis or 
Gram-positive bacteremia, among other indications, 
mostly as an alternative to glycopeptides (such as 
vancomycin) or penicillin allergy (Liu et al., 2011; 
Cosgrove, Avdic, Dzintars, 2015). In any case, the 
general recommendation is to prescribe daptomycin 
after discussion with an infectious diseases specialist 
to increase the chances of good results (Rae, 2014; 
Esposito et al., 2016) and take into account elements 
such as microbiology data (e.g., culture, MIC).
In 2009, daptomycin was authorized in Brazil 
for the treatment of complicated infections of skin 
and soft tissue caused by Gram-positive bacteria 
(dosing = 4 mg/kg once daily over 7–14 days or until 
the infection is resolved) and infection by S. aureus, 
including those associated with right-side infectious 
endocarditis (dosing = 6 mg/kg once daily for 14–42 
days) (Anvisa, 2017).
In 2014, 1,500 doses of daptomycin were dispensed 
at the National Institute of Orthopedic Surgery (INTO) 
of Rio de Janeiro, Brazil, a 310-bed specialized center. 
That year, the cost of this antibiotic amounted US 
$162,312.0 a figure that represented 3.6% of the total 
pharmaceutical expenditure of the INTO. Due to the 
restrictive conditions on the use of daptomycin, as well 
as its high price, a study was carried out to describe all 
the patients that received daptomycin while admitted to 
this orthopedic research hospital. 
Daptomycin was introduced in the INTO in 2009, 
but its prescription pattern was not assessed until the time 
of this study and there are not enough results in Brazil. 
The objectives of this study were to evaluate 
the clinical outcomes of daptomycin therapy and the 
adherence to treatment recommendations.
MATERIAL AND METHODS
The study was carried out in the National Institute 
of Orthopedic Surgery (INTO) in Rio de Janeiro, Brazil. 
The institution is a 310-bed specialized tertiary hospital 
that performs highly complex surgeries in orthopedics; 
the occupancy rate is 75% annually.
Compliance with ethical standards
This study was approved by the Ethics Committee 
of National Institute of Orthopedic Surgery (INTO) 
with protocol number 00045.0.305.000-11. All ethical 
requirements were followed for the study according 
to resolution number 466/2012 involving studies with 
human beings in Brazil. 
Design and selection inclusion criteria 
A retrospective cohort study was conducted among 
those patients admitted to the National Institute of 
Orthopedic Surgery (INTO) between January 2010 
and December 2014. The nonprobabilistic sample 
of convenience included all patients admitted to the 
institution, according to the following inclusion criteria: 
18 years old or more, any number of hospitalization 
days, and administration of daptomycin.
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Collection of information and 
definition of the variables
Demographic, microbiological, and clinical 
outcome data, as well as information on antimicrobial 
treatment, were collected using a standardized case 
report form and were collected directly from the 
patient’s records.
The independent variables were reason for 
hospitalization, age, gender, number of underlying 
diseases, number of concomitant drugs, type of infection, 
microbiological results, previous and concomitant 
antibiotic therapy, previous and concomitant beta-
lactam therapy, concomitant antibiotic therapy, and 
daptomycin therapy.
The dependent variable or the outcome of patients 
was already defined in previous published studies from 
a clinical and microbiological standpoint, according to 
the following criteria: 
“clinical success” or “total response” corresponds 
to a cure and/or microbiologically negative samples at 
the end of treatment (Liu et al., 2011; Marc et al., 2014).
“Treatment failure” included the following (Marc et 
al., 2014): persistence of the infectious syndrome despite 
daptomycin treatment and requiring a modification of 
the antibiotic therapy; and death of the patient, whatever 
the cause. In the present study it was considered whether 
death was attributable to the infectious syndrome or not, 
according to the clinician, and/or to an adverse effect 
attributable to the agent.
“Adherence and nonadherence” to clinical 
guidelines (CGs) or recommendations was assessed by 
taking into account the appropriate use of daptomycin 
that was based on the identification of the organism (e.g., 
bacteremia with suspected MRSA, osteomyelitis caused 
by MRSA with a vancomycin MIC > 1.5 mg/mL, and 
coagulase-negative staphylococcal infections where 
the vancomycin MIC ≥4 mg/mL), dose and time of 
therapy according to the site of infection, management 
of persistent MRSA bacteremia, and vancomycin 
treatment failures. In case a consideration described in 
the clinical guidelines was not followed, the condition 
was classified as “nonadherence” (Liu et al., 2011).
Regarding indications of use, it was considered an 
“off-label prescription” when daptomycin was given to 
patients presenting an infection not appearing in the 
summary of product characteristics (SPCs) approved 
by the Brazilian Medicines Agency (ANVISA). The 
indications of use of daptomycin approved by ANVISA 
in Brazil did not differ from those approved by the FDA 
and EMA.
Statistical analysis
The demographic and clinical characteristics 
associated with the therapeutic response were compared 
using a bivariate analysis. To compare categorical 
variables, clinical success, and treatment failure, a chi-
square test and Fisher’s exact test were used. For the 
association of variables with clinical success (dependent 
variable), a multiple logistic regression model was used, 
which indicated the chances of clinical success through 
an odds ratio. We used SPSS and a 5% significance level 
in all analyses.
RESULTS
During the study period, 52 patients (33 women; 
63.5%) admitted to the INTO were prescribed 
daptomycin for the treatment of bacteremia (11 patients; 
21.1%) or osteoarticular infections (osteomyelitis 33; 
63.5%, and synovial fluid 8; 15.4%) and followed the 
inclusion criteria. Table I shows that the most frequent 
comorbidities were arterial hypertension (26 patients, 
50.0%) and type 2 diabetes mellitus (7 patients; 13.4%). 
The mean of hospitalization was 67 days (SD = 48.9). 
More than a half of patients of the cohort showed 
clinical success (27; 51.9%), while treatment failure was 
recorded in the remaining 25 (48.1%), being that five 
patients died (9.6%).
TABLE I - Demographic and clinical characteristics of the 











Female 14 (51.8) 19 (76.0)
Male 13 (48.2) 6 (24.0)
Age (years) NS1
< 65 17 (62.9) 10 (40.0)
≥ 65 10 (37.1) 15 (60.0)
(continuing)
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TABLE I - Demographic and clinical characteristics of the 













0 13 (48.1) 3 (12.0)




1-13 1 (3.7) 0
14-34 4 (14.8) 6 (24.0)
35-55 8 (29.7) 6 (24.0)




< 10 12 (44.5) 10 (40.0)
≥ 10 15 (55.5) 15 (60.0)
Types of infection 0.024
Bone 21 (77.8) 12 (48.0)
Synovial fluid 1 (3.7) 7 (28.0)




MRSA2 17 (63.0) 12 (48.0)
S. aureus coagulase 
negative3
6 (22.2) 4 (16.0)




Yes 21 (77.8) 24 (96.0)
No 6 (22.2) 1 (4.0)
(continuing)
TABLE I - Demographic and clinical characteristics of the 













Yes 16 (59.0) 16 (64.0)
No 11 (41.0) 9 (36.0)
Concomitant 
antibiotic therapy NS1
Yes 20 (74.0) 19 (76.0)




Yes 11 (40.8) 12 (48.0)




Yes 9 (33.4) 8 (32.0)




< 500 0 1 (4.0)






Yes 7 (25.9) 1 (4.0)
No 20 (74.1) 24 (96.0)
1NS = not significant; *Fisher’s exact test; 2MRSA=methicillin-
resistant Staphylococcus aureus; 3S. coagulase negative (S. 
epidermidis, S. constellatus, and S.capitis)
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Previous and concomitant antibiotic treatment
Most patients (45 out of 52; 86.5%) received 
daptomycin as a second-line treatment; the antibiotics 
prescribed previously were glycopeptides (37/45, 82.2%; 
vancomycin, n = 33; and teicoplanin, n = 4), and/or beta-
lactams (32/45, 71.1%; piperacillin + tazobactam, n = 
22, meropenem, n = 13, and oxacillin, n = 6). The first 
antibiotic had been switched to daptomycin because 
of treatment failure (31/45; 68.9%) or adverse drug 
reactions (ADRs; 14/45; 31.1%).
Only 13 patients of the INTO cohort (25.0%) 
received daptomycin alone. The remaining 39 patients 
(75.0%) were prescribed daptomycin in combination 
with other antibiotics; the most frequent ones were beta-
lactams (23/39; 59.0%) or rifampicin (9/39; 23.0%).
Adherence to guidelines and recommendations
Table II shows adherence to different aspects of 
the clinical recommendations for daptomycin use. It 
is to be noted that daptomycin was selected as a first-
line treatment in 7 patients (13.5%) and that 8 patients 
(15.4%) received daptomycin to treat synovial fluid 
infection. None of these situations were recommended.
Up to 5 patients (9.6%) had S. aureus coagulase 
negative without data on MIC for daptomycin, and 
13 patients (25.0%) had infections caused by other 
pathogens. Thus, in 18 out of 52 patients (34.6% of the 
cohort), the guidelines had not been followed regarding 
microbiological aspects.
The mean daptomycin prescribed dose was 557 mg/
day (SD = 146.6); most patients (42; 80.7%) were given 
the standard 500 mg/day dose. Four patients had chronic 
kidney disease (7.7%), and the daptomycin dosing 
regimen had been one dose every 48 hours, according 
to the recommendations. It is to be noted that neither 
the body weight nor the body mass index (BMI) were 
calculated for any patient in this cohort.
Daptomycin was prescribed by infectious disease 
specialists in 32 out of 52 patients (61.5%) of the study 
cohort. The remaining 20 prescriptions were originated 
by intensive care physicians (14/52; 27.0%) or general 
doctors (6/52; 11.5%).
Thus, taking into account the different aspects 
considered in the clinical recommendations for the use 
of daptomycin, complete adherence was found in only 
15.4% of the patients of the study (8/52).
TABLE II - Adherence to different aspects of the clinical recommendations for daptomycin use and clinical success or failure 







Indication of use (identification of an organism) NS1
Recommended 20 (74.0) 13 (52.0) 33
Nonrecommended 7 (26.0) 12 (48.0) 19
Line therapy NS1
Second 21(77.8) 24 (96.0) 45
First 6 (22.2) 1(4.0) 7
Pathogen NS1
MRSA2 19 (70.4) 15 (60.0) 34
Others organisms 8 (29.6) 10 (40.0) 18
(continuing)
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TABLE II - Adherence to different aspects of the clinical recommendations for daptomycin use and clinical success or failure 








Infectologist 20 (74.0) 12 (48.0) 32
Others 7 (26.0) 13 (52.0) 20
Previous vancomycin therapy NS1
Yes 19 (90.0) 10 (83.3) 29
No 2 (10.0) 2 (16.7) 4
Dose and time therapy (according with 
the side of infection and organism)
NS1
Recommended 7 (26.0) 5 (20.0) 12
Nonrecommended 20 (74.0) 20 (80.0) 40
1NS = not significant; 2MRSA=methicillin-resistant Staphylococcus aureus; *Chi-square test
clinical success. Among the 25 patients in the treatment 
failure group, 52.0% had the drug prescribed by general 
doctors or intensive care physicians (Rae, 2014), while 
among the 27 patients of the clinical success group, 
74.0% had it prescribed by an infectious disease 
specialist (Montange et al., 2014).
Taken as a whole, patients seem to have more 
chance of clinical success if the duration of daptomycin 
therapy was according to guideline indications (OR = 
16.86; 95% CI = 1.45-195.88) and seem to have more 
chance of success if daptomycin was prescribed by a 
specialist in infectious diseases (OR = 4.84; 95% CI = 
1.11-21.09) (Table III).
In this study, five patients (9.6% of the cohort) 
died. It is interesting to highlight that none had followed 
the guideline recommendations. Four patients presented 
osteomyelitis and one bacteremia, two were colonized 
by MRSA, and the remaining three by Staphylococcus 
capitis, Staphylococcus epidermidis, and Pseudomonas 
aeuroginosa (1 patient each). Their comorbidities 
included hypertension (3 patients) and obesity and 
vestibular disease (1 each). In this group, just 1 
Clinical success
Clinical success or “cure” was achieved by 51.9% 
of the patients undergoing therapy with daptomycin 
(27 out of 52 patients). The proportion of clinical 
success increased to 59.1% if only patients treated for 
osteomyelitis and bacteremia were considered (26 cured 
out of 44 patients).
Among the clinical success group, the mean duration 
of treatment with daptomycin was 35 days (SD = 24.5) 
and the daily dose was 565 mg/day. Just one patient had 
infection in synovial fluid and was cured; this patient 
was infected by S. aureus coagulase negative.
Among the 25 patients who showed treatment 
failure (48.1%), 24 had received previous antibiotic 
therapy, 67% with glycopeptides (16/24), vancomycin 
(16/16), and/or teicoplanin (2/16). The mean duration of 
the therapy with daptomycin was 22 days (SD = 16.9) 
and the daily dose was 550 mg/day.
The mean duration of the therapy with daptomycin 
was 28 days (SD = 16.7) in the group with treatment 
failure and 24 days (SD = 22.0) in the group that found 
Nonadherence to treatment recommendations is a factor contributing to the clinical failure of daptomycin: Cohort study in Brazil
Braz. J. Pharm. Sci. 2020;56: e17184 Page 7/10
patient had not been treated with vancomycin, and the 
daptomycin prior to the dose used was 500 mg/kg/day. 
TABLE III - Logistic regression analysis of variables associated 
with success in the 52 orthopedic patients undergoing therapy 




Underlying disease 0.52 0.05-4.69
Types of infection 0.46 0.06-2.83




Prescriber: Infectologist 4.84 1.11-21.09
*Logistic regression model
DISCUSSION
The analysis of the 52 patients treated with 
daptomycin that constituted the INTO cohort showed 
clinical success in 51.8% of the cases. This proportion 
is clearly lower than those reported in other published 
cohorts, which ranged from 71.0% to 96.0% of treated 
patients (Seaton et al., 2013; Fossaseca, 2007). A closer 
look at the INTO patients also showed 87.5% clinical 
success (7/8 patients) among those strictly following 
the clinical guidelines, and only 45.5% clinical 
success among those who did not follow the clinical 
recommendations. This result is important, because it 
shows the actual use of an allegedly reserve antibiotic in 
the daily practice of a specialized hospital, far from the 
methodological conditionings of some published study 
cohorts such as the Cubicin Registry and Experience 
(CORE) and EUCORE (Vilhena, Bettencourt, 2012; 
Gonzalez-Ruiz et al., 2011; Marc et al., 2014; Seaton et 
al., 2013; Timerman et al., 2013). 
Retrospective studies that investigated the guideline 
for daptomycin use found 65.0-75.0% clinical success 
(Holtom et al., 2007; Lamp et al., 2007). 
A French study that investigated the use of 
aminoglycosides but did not use daptomycin yielded 
a different result about the use of the guidelines. This 
study showed that 65.2% of patients had a clinical 
indication but that the guideline for the drugs was 
followed just in 23.2% of the cases. The evaluation still 
showed that the guideline found drug concentration at 
the peak and trough aminoglycoside in 24.9% and 67.4% 
of the cases, respectively. This study reinforces the use 
of the guideline, especially in cases with a high risk of 
underdosing (Robert et al., 2017).
Another study that investigated Dutch guidelines 
for patients with urinary tract infections and that used 
catheters compared to empirical therapy found that the 
inadequate coverage of the guideline ranged from 3.0% 
to 24.0% for patients using a catheter. Patients submitted 
to the guideline presented a broader spectrum, but the 
continuous epidemiological changing of the resistance 
rates reinforces the need to improve the adherence to 
the guideline to increase coverage rates (Spoorenberg 
et al., 2013).
A 2010 retrospective study at the Bichat-Claude-
Bernard teaching hospital in Paris that observed the 
evolution of daptomycin prescriptions showed that 95% 
of daptomycin prescriptions were off-label, most did not 
comply with local guidelines, and more than a half of 
the treatments were prescribed both off-label and not 
according to local recommendations (Marc et al., 2014).
As an antibiotic with high efficacy and a good 
safety profile, according to published studies showing 
a tendency to use daptomycin empirically in cases with 
clear and restrictive indications both in the EMA, FDA, 
and ANVISA SPCs and MRSA osteomyelitis, a study 
that analyzed patients who received daptomycin after 
failed with previous treatment found clinical success 
for all nine patients, but one relapsed, thus 89.0% had 
clinical success (Finney, Crank, and Segreti, 2005). 
In order to be as comprehensive as possible, 
MRSA osteomyelitis was considered as an “approved” 
or “allowed” indication, taking into account the 
microbiological causal agent in the INTO cohort; 
otherwise a more restrictive analysis following the 
Brazilian recommendations would have reduced 
adherence to the recommendations even more.
An additional interesting practical observation is 
that the INTO cohort included hospitalized orthopedic 
patients; these were patients with low or no mobility and 
prolonged hospital stays, which makes difficult to know 
their weight and BMI. As dosage recommendations are 
based on BMI calculations, none of the included patients 
could strictly follow the guideline. 
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So, considering adherence to the guideline, dosage 
individualization was considered to be “calculated 
according the recommendations” in all cases. The fact 
was that, in the INTO cohort, the dosage was calculated 
from a standard estimated weight of 75–80 kg. This 
could also explain part of the treatment failure observed 
in the cohort of patients, because unadjusted dosages by 
body weight or BMI could result in doses below those 
needed. Due to the frequency of infections produced by 
daptomycin-susceptible microorganisms in patients with 
poor mobility, this factor should be taken into account in 
the recommendations for use and in future studies.
Up to eight patients received daptomycin for a 
synovial fluid infection, of which seven experienced 
treatment failure. This is an unapproved indication of 
use even if it is caused by MRSA, and, to our knowledge, 
the only published evidence is a study with 16 healthy 
volunteers that showed a 54.0% concentration of 
daptomycin in synovial fluid after infusion of 8 mg/kg 
(Sakoulas et al., 2009). This use seems an extrapolation 
of results, something that could be frequent in real 
clinical practice but that should be avoided. 
Finally, five patients died while they were on 
treatment with daptomycin. All of them were complicated, 
with longer hospitalization. Due to the characteristics 
of the source database, it is not possible to establish 
or to rule out any causal relationship. The main point 
here is that none of these patients had been prescribed 
daptomycin according to any recommendation of use.
Clinical success can improve when the antibiotics 
are prescribed by specialists (Rae, 2014; Esposito et 
al., 2016). A study that evaluated treatments and results 
before and after specialist consultations that applied the 
guideline found an increase of specific results, negative 
cultures, and an improvement in diagnosis and therapy 
appropriateness, with statistical significance (p < 0.001) 
(Esposito et al., 2016).
All these findings point to the need to reinforce 
clinical guidelines and recommendations in some 
aspects: (1) to ensure that these guidelines and 
recommendations are coherent with the most relevant 
published evidence; (2) to strengthen the implementation 
process of any new guideline or recommendation of use 
once a new medicine is included in a hospital formulary; 
and (3) to encourage potential prescribers to adhere to 
clinical guidelines in order to avoid treatment failure, 
unnecessary side effects, or inefficient expenditures.
The limitations of the present study are its 
observational and retrospective design, in that some 
missing or inaccurate information in the clinical charts 
could have biased the results presented herein. This could 
be the case for the five patients who died, as a recorded cause 
of death was the unspecific “cardiorespiratory arrest.” On 
the other hand, the observational character of the study 
has obvious advantages for analyzing the behavior of 
prescribers in noncontrolled and real day-to-day clinical 
activity. Besides this, the lack of drug sensitivity of the 
bacteria involved was not investigated and would be 
important for future studies. Off-label prescriptions must 
respect some conditions to be considered acceptable 
(e.g., no available alternative drug, “indispensability” as 
judged by the prescriber, and free and informed patient 
consent) (Marc et al., 2014). None of these conditions 
were explicitly present in the INTO cohort. Thus, despite 
their limitations, observational studies complement the 
experimental ones and help to identify processes and 
decisions that can improve research.
As happens with many drug utilization studies, 
the external validity of the results can be questioned. 
Notwithstanding this, drug utilization studies are useful 
to raise problems that can be addressed in the hospital 
where the study was carried out and at the same time, 
identify potential causes of therapeutic failure that could 
be investigated in other clinical settings. Especially in 
this research, the results reinforce the importance of the 
guideline for using daptomycin. 
Despite well-defined conditions for using 
daptomycin, there are different aspects that could 
favor more generalized and inappropriate use or even 
off-label use of this antibiotic agent. The published 
evidence describing high rates of success, an acceptable 
safety profile, and good to excellent blood, urine, and 
joint concentrations could contribute to this generalized 
use. Inappropriate use of a second-line antibiotic such as 
daptomycin, in addition to its excessive and unnecessary 
cost, can increase the appearance of resistant pathogens, 
a growing and worrying problem all over the world.
The inappropriate use of medicines is a global 
phenomenon, and it should be taken into account as 
a factor contributing to the clinical failure of a given 
active ingredient.
CONCLUSIONS
This study shows that patients have more of a chance 
of clinical success with daptomycin when the therapy 
follows the guideline indications and when daptomycin 
is prescribed by a specialist in infectious diseases. 
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Regarding adherence to guidelines, the dosage of the 
antibiotic had to be prescribed by applying a standard 
estimated weight of 75–80 kg as it is challenging to 
measure the weight or calculate the BMI of orthopaedic 
patients. So, none of the included patients could strictly 
follow the guideline. Because of that, doses could have 
been unadjusted for body weight or BMI, and below 
the doses needed, which would have impacted on the 
infections. These aspects are important for minimizing 
early resistance to reserve antibiotics and adverse 
reactions due to a drug that may not have been the 
most suitable for a given patient, to avoid unnecessarily 
elevated pharmacy expenditures, and to promote better 
use of medicines.
Adhering to treatment recommendations, the 
dosage of the antibiotic was prescribed by applying a 
standard estimated weight of 75–80 kg because it is very 
difficult to measure the weight or calculate the BMI of 
orthopedic patients. So, none of the included patients 
could strictly follow the guideline. Because of that, 
doses could have been unadjusted for body weight or 
BMI, and below the doses needed, which would have 
impacted on the infections.
These aspects are important for minimizing early 
resistance to reserve antibiotics and adverse reactions due 
to a drug that may not have been the most suitable for a 
given patients, to avoid unnecessary elevated pharmacy 
expenditures, and to promote a better use of medicines.
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